- Home
- NCV vs NGEN Comparison
NCV vs NGEN Comparison
Compare NCV & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NCV | NGEN |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.8M | 317.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NCV | NGEN |
|---|---|---|
| Price | $16.38 | $4.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 101.2K | ★ 128.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.51 | $3.73 |
| 52 Week High | $16.70 | $5.93 |
Technical Indicators
Market Signals| Indicator | NCV | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.92 | 37.03 |
| Support Level | $15.55 | $3.73 |
| Resistance Level | $16.70 | $4.50 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 72.33 | 45.45 |
Price Performance
Historical ComparisonAbout NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.